spec sheet10 rows
TB-500 is a synthetic peptide based on a fragment of thymosin beta-4, a naturally occurring actin-regulating protein involved in cell migration, angiogenesis, and tissue repair. By buffering the cell's pool of actin it promotes the cell movement that closes wounds and builds new blood vessels; notably, its parent protein was the first molecule shown to switch the dormant adult heart's outer layer back into its embryonic vessel-building program after injury. Thymosin beta-4 itself has been advanced into human trials for wound healing, dry eye, and cardiac repair, while TB-500 is used as a research peptide and is prohibited in sport.
- Recovery accelerant for battered soft tissue
- Drives the cell migration that closes wounds
- Sparks new blood vessel growth
- Calms inflammation right at the injury site
- Flexibility and range of motion often improve
- Built on thymosin beta-4, a repair heavyweight
- Human safety data are limited; most evidence is preclinical
- Injection-site reactions such as redness or irritation are possible
- Temporary fatigue or lethargy has been reported anecdotally
Overview
TB-500 is a synthetic peptide derived from thymosin beta-4, a small actin-binding protein that occurs naturally throughout the body. Thymosin beta-4 is a highly conserved peptide of roughly 43 amino acids that was first isolated from calf thymus tissue more than four decades ago; it is present in most tissues and cell types and reaches especially high concentrations in blood platelets, neutrophils, and other cells involved in repair [3][2]. It is the most abundant member of the beta-thymosin family, accounting for an estimated 70 to 80 percent of all beta-thymosins in human cells [1]. Products sold as TB-500 are marketed as a synthetic form of this peptide, or of its central actin-binding region, and are used chiefly for tissue repair and recovery.
The biological interest in thymosin beta-4 stems from its central role in regulating actin, the cytoskeletal protein that drives cell movement. By binding and sequestering monomeric actin, the peptide influences the assembly and disassembly of the actin cytoskeleton and thereby the motility, migration, and differentiation of cells during healing [1][2]. Building on this, research has documented roles in angiogenesis, wound healing, hair growth, anti-inflammation, and protection of the heart, brain, cornea, and other organs [1][5].
Thymosin beta-4 has been formally developed as a therapeutic candidate. The biopharmaceutical company RegeneRx advanced it into multicenter clinical trials for dermal, corneal, and cardiac wound repair, and it entered phase 1 testing for cardiovascular disease [3][5]. Despite this pedigree, TB-500 as sold in the peptide market is not an approved medicine; it is used in research and veterinary contexts, is administered by injection, and is prohibited in competitive sport. Much of the supporting evidence to date derives from cell and animal models, with human therapeutic use still investigational [4][6].
- Thymosin beta-4, the basis of TB-500, is the major actin-sequestering peptide in mammalian cells, binding actin in a precise one-to-one ratio to control cell movement.
- Its parent protein was the first molecule shown to reawaken the adult heart's outer layer into the embryonic blood-vessel-building program after injury.
Mechanism
The core molecular action of thymosin beta-4 is the regulation of actin. It functions as the principal G-actin sequestering in mammalian cells, binding monomeric (globular) actin in a one-to-one ratio and holding it in reserve; this controls the pool of actin available for polymerization into filaments and so governs the constant treadmilling of the actin cytoskeleton [1]. Because cell movement depends on coordinated actin assembly and disassembly, this single biochemical property underlies the 's broad effects on cell motility, migration, and shape change during tissue repair [1][2].
From this foundation flow the regenerative benefits that make the attractive. Thymosin beta-4 promotes angiogenesis, the formation of new blood vessels, and in the heart it releases the adult epicardium from quiescence, stimulating epicardium-derived progenitor cells to migrate inward and differentiate into endothelial and smooth muscle cells that build new vasculature [4]. It recruits pericytes and stabilizes the endothelial barrier, actions that preserved microcirculation, raised blood pressure, and improved survival in an animal model of sepsis [7]. Across the vasculature it participates in vasculogenesis, angiogenesis, arteriogenesis, and extracellular matrix remodeling, with exogenous enhancing capillary formation and pericyte recruitment in injury models [6]. It also carries antiapoptotic and anti-inflammatory properties and supports stem and progenitor cell differentiation, cell migration, and survival, which together provide the rationale for its wound-repair and neurorestorative applications [5].
In injury settings these mechanisms translate into accelerated wound healing, enhanced neovascularization, and functional recovery. In experimental traumatic brain injury, thymosin beta-4 amplified endogenous neurorestorative processes, including angiogenesis, , and axonal remodeling, and improved functional outcomes [5]. Reflecting its origin, the therapeutic molecule is the same roughly 43-amino-acid found naturally in tissue [3]. Most of this evidence remains preclinical, and while early human trials have supported safety and tolerability, robust efficacy data in people are still limited [3][6].
receptor fingerprint
Actin / cell migrationregulates
Angiogenesis (blood vessels)promotes
Inflammation / apoptosisreduces
Safetyrisks and cautions, not medical advice
TB-500 is a synthetic peptide related to thymosin beta-4 marketed for injury recovery; it is not approved for human use and has essentially no controlled human safety data. Reported effects are largely anecdotal, such as injection-site reactions and transient fatigue or head-rush. Because thymosin beta-4 promotes blood-vessel formation and cell migration, there is a theoretical concern that it could promote growth of existing tumors, and its long-term safety is unknown.
Reconstitutionarithmetic only, not dosing advice
arithmetic only; not medical or dosing advice.
History
TB-500 is a synthetic peptide based on thymosin beta-4, a naturally occurring protein first isolated from thymus tissue by Allan Goldstein and colleagues, who pioneered the study of thymic peptides beginning in the 1960s and 1970s. Thymosin beta-4 was later recognized as the principal actin-sequestering peptide in mammalian cells, binding monomeric actin one-to-one and thereby regulating the cytoskeletal dynamics that drive cell migration and tissue repair.
Landmark cardiac research subsequently showed that the parent protein could reawaken the dormant adult heart's outer layer, coaxing epicardium-derived cells back into their embryonic blood-vessel-building program after injury. Thymosin beta-4 itself has since been advanced into human trials for wound healing, dry eye, and cardiac repair, while the closely related fragment marketed as TB-500 is used as a research peptide and is prohibited in sport.
Reputation
TB-500 is popular in the recovery and regenerative peptide community for its association with thymosin beta-4's broad roles in wound healing, angiogenesis, and cell migration. Its appeal is strengthened by a genuinely striking scientific pedigree; the parent protein was the first molecule shown to switch the adult heart back into a vessel-building mode, a finding that drew serious cardiovascular research interest.
Preclinical data across injury, sepsis, and traumatic brain injury models have been consistently supportive, which fuels enthusiasm for its tissue-repair potential. Responsible discussion emphasizes that most of this evidence remains preclinical, that human efficacy data are still limited despite reassuring early safety signals, and that TB-500 is banned by anti-doping authorities. It is best understood as a scientifically interesting peptide whose animal-model promise has yet to be fully confirmed in people.
Subjective profileweighing the evidence above
Popular well ahead of its evidence. The repair and angiogenesis biology is real in animals, but there are essentially no controlled human safety data, and a compound that drives new blood vessel growth is a poor idea for anyone with a cancer history. Sleep, protein and loading progression will do more.
Where to buy
Suppliers
Vendors carrying TB-500, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
Exceed Enhancement
TB-500
Moglabs
TB-500
Kimera Chems
TB-500
Peptira
TB-500
RUPharma🌐
Thymosin Beta-4
RUO
TB-500
Research
- 2003first citedThymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induc…
- 2015most active year4 papers
- 2025most recentThymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals
- 1.Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications
- 2.The beta-thymosins: intracellular and extracellular activities of a versatile actin binding protein family
- 3.Development of thymosin beta4 for treatment of patients with ischemic heart disease
- 4.Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium
- 5.Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury
- 6.Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease
- 7.Thymosin β4 attenuates microcirculatory and hemodynamic destabilization in sepsis
- 8.Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo
- 9.Thymosin beta4 induces epicardium-derived neovascularization in the adult heart
- 10.Epicardial progenitor cells in cardiac regeneration and neovascularisation
- 11.Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart
- 12.Cardioprotection by Thymosin Beta 4
24 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is TB-500?
It is a synthetic fragment related to the naturally occurring protein thymosin beta-4, studied for its role in cell migration and tissue repair.
Is it commonly paired with other peptides?
It is frequently discussed alongside BPC-157, as some people use them together for recovery-focused protocols.
Is TB-500 approved for human use?
It is generally sold as a research chemical and is not an approved therapeutic, so human safety data remain limited.
How is it typically administered?
It is usually reconstituted from powder and given by injection; it is not effective orally due to breakdown in the gut.
Adverse effects
- Human safety data are limited; most evidence is preclinical
- Injection-site reactions such as redness or irritation are possible
- Temporary fatigue or lethargy has been reported anecdotally
- Theoretical concern that pro-angiogenic activity could be undesirable in the presence of tumors
Notes and cautions
- Not approved for human therapeutic use and prohibited in competitive sport
- No published study has administered thymosin beta 4 or its TB-500 fragment by the intranasal route. Searches under thymosin beta 4, thymosin beta4 and TB-500, crossed with intranasal, nasal, nostril and nose to brain terms, return no such paper. Work on other mucosal routes exists, including aerosol delivery to the lung and ophthalmic drops, but neither is the nasal route and neither says anything about nasal absorption. Whether the peptide crosses the nasal epithelium at all is unmeasured, and no nasal dose, absorption figure or tolerability series exists for it.